Anson Funds Management’s ImmunityBio IBRX Stock Holding History

Anson Funds Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$133K	–	269
2020 Q4	$133K	Buy	+10,000	New	+$96.2K	0.03%	160

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Anson Funds Management's IBRX Position: Q1 2021 in Review

Anson Funds Management sold out of ImmunityBio (IBRX) in Q1 2021, closing a stake of 10,000 shares — an estimated $133K sold.

Anson Funds Management first reported a position in IBRX in Q4 2020 and held it in 1 quarter. The position peaked at $133K in Q4 2020. 126 funds tracked by Wall St. Rank hold IBRX as of Q1 2021.

Anson Funds Management reported no remaining ImmunityBio position as of Q1 2021 after selling out during the quarter.
Anson Funds Management sold 10,000 ImmunityBio shares in Q1 2021, an estimated $133K.
Anson Funds Management first reported a position in ImmunityBio in Q4 2020 and held it in 1 quarter.
Anson Funds Management's ImmunityBio position peaked at $133K in Q4 2020.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.